Gilead Sciences Inc. DL-Notes 2016(16/27)
Type of financial instrument
Corporate Bond
Sub-Type
Technology
Yield
4.42
Yield spread Bundesanleihe
1.6974
Tradable for private investors
No
Minimum amount tradeable unit
2,000.00
Maturity
01/03/2027
Interest Rate
2.95 %
Currency
US Dollar
Facts & figures
Price data
| TRADE PLATFORM | ||
| LAST PRICE / YIELD | 99.154 G / 4.42 | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 09:45:55 PM | |
| DAILY VOLUME (NOMINAL) | 0 | |
| YIELD SPREAD | 1.6974 | |
| FIXINGPRICE | - | |
| DAILY HIGH / LOW | 99.189 | 99.147 |
| PREV. DAY'S PRICE | 99.159 | (07/20) |
| CHANGE DAY BEFORE | -0.01 | -0.01 % |
| 52 WEEK HIGH / LOW | 99.269 (02/17) | 97.89 (08/01) |
Master Data
| WKN | A186KM |
| ISIN | US375558BM47 |
| SYMBOL | - |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Corporate Bond |
| SUB-TYPE | Technology |
| ISSUER | Gilead Sciences Inc. |
| S&P RATING | Please log in to view this field |
| (TRADING) SEGMENT / TICKS | -/ - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| INTEREST RATE | 2.95 % |
| INTEREST RUN FROM | 20/09/2016 |
| NEXT INTEREST PAYMENT | 31/08/2026 |
| UNIT INTEREST FROM NOMINAL AMMOUNT | 1.213 % |
| TRADING CURRENCY / NOTATION | US Dollar/ Percent |
| NOMINAL CURRENCY | US Dollar |
| SETTLEMENT CURRENCY | Euro |
| QUOTATION | Continuous trading |
| ISSUING VOLUME | 1.25 Bil. |
| MINIMUM AMOUNT TRADEABLE UNIT | 2,000.00 |
| SMALLEST TRADEABLE UNIT | 1,000.00 |
| MATURITY | 01/03/2027 |
| MARKET MAKER | - |
| STEP UP/ DOWN WHEN RATING CHANGES | No |
| STEP UP FIXED AT ISSUE | No |
| STEP DOWN FIXED AT ISSUE | No |
| BOND CALLABLE BY THE ISSUER | Yes |
| BOND IS SUBORDINATED | No |
Description
Local currency bond: USD. Make Whole Call Option. Callable bond.
Tradability Information
Please log in to see the tradability information for this stock.Not registered yet? Create your free account here.
Company profile
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.